New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.

@article{Itoh2007NewPO,
  title={New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.},
  author={Yukoh Itoh and Yoshihiro Komohara and Nobukazu Komatsu and Takafumi Minami and Koujiro Saito and Masanori Noguchi and Kyogo Itoh and Mamoru Harada},
  journal={Oncology reports},
  year={2007},
  volume={18 5},
  pages={1231-7}
}
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is linked to aggressive prostate cancer and could be an appropriate target in specific immunotherapy. In this study, we attempted to identify EZH2-derived peptides that have the potential to generate cancer-reactive cytotoxic T lymphocytes (CTLs) in human leukocyte antigen (HLA)-A2+ prostate… CONTINUE READING